Noelle Dubiansky is an associate in the firm’s Technology & Life Sciences Group. She joined Goodwin in 2014.

Ms. Dubiansky represents biotechnology, pharmaceutical, medical device, and other life science companies in a wide range of intellectual property and commercial transactions. She regularly advises private and public companies on complex commercial transactions, including strategic partnerships, licensing, technology acquisition, research and development collaborations, clinical testing, contract services, distribution and manufacturing agreements. Ms. Dubiansky also regularly counsels clients in connection with private financings, public offerings, spin-outs and M&A transactions with respect to intellectual property rights and operational risks.

Prior to joining Goodwin, Ms. Dubiansky was an associate in the Life Sciences practice group at Cooley LLP and previously, in the FDA group at Hyman, Phelps & McNamara.

While attending law school, Ms. Dubiansky was named an Edward F. Hennessey Scholar.

Experience

ERFAHRUNG

工作经历

A selection of her recent representations includes:

  • Warp Drive Bio in its strategic collaboration with Roche to discover and develop novel classes of antibiotics, for a deal value of up to $387 million.
  • Lysosomal Therapeutics in its exclusive option arrangement with Allergan plc.
  • BlueRock Therapeutics, a next-generation regenerative medicine company, in its $225 million financing by Bayer and Versant Ventures and seminal in-licenses and alliances with Memorial Sloan Kettering, the Centre for Commercialization of Regenerative Medicine and University Health Networks.
  • Cerevance in its launch by Lightstone Ventures and Takeda Pharmaceutical, which included $36 million in financing and seminal in-licenses with Takeda.
  • Brammer Bio in its acquisition of a biologics manufacturing facility from Biogen.
  • Galapagos NV in connection with its $2 billion strategic collaboration with Gilead Sciences, Inc., including $300 million upfront and a $425 million equity investment. The deal was named the Top Biopharmaceutical Licensing Deal at the 2016 Allicense Deals of the Year.
  • Voyager Therapeutics in its $845 million collaboration and option agreement with Genzyme Corp. to develop and commercialize novel gene therapies for central nervous system disorders.
  • Warp Drive Bio in its strategic partnership with Sanofi
  • Lycera in connection with its $83 million global collaboration with Celgene Corporation
  • Teva in its $3.2 billion acquisition of Auspex Pharmaceuticals, Inc.
  • Foundation Medicine in its collaboration agreement and equity transaction with Roche, with a total value in excess of $1 billion.
  • Forma Therapeutics in its $600 million collaboration and option agreement with Celgene Corp., and follow-up  $200 million strategic collaboration agreement, to develop and commercialize drug candidates to regulate protein homeostasis targets.*
  • Molecular Partners AG in its strategic collaboration with Allergan with a total potential deal value of more than $1.4 billion.*

* Certain representative matters prior to joining Goodwin

Recognition

Ms. Dubiansky has been recognized as a Washington D.C. Super Lawyers “Rising Star” by the Washington Lawyer magazine.

In The News

MELDUNGEN

在新闻中

Credentials

WERDEGANG

专业资格

Education

J.D., 2005
Boston University School of Law

Intellectual Property concentration (honors)

B.A., 1999
Boston University

Biology

Admissions

Bar

District of Columbia
Massachusetts
New York
Virginia
Get In Touch
KONTAKT
Get In Touch
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
搜寻其他律师